Prevalence and outcomes of patients taking oral corticosteroids for over 1 month undergoing major surgery in England 2010-2020

2010-2020年英格兰接受大型手术且服用口服皮质类固醇超过1个月的患者的患病率和预后

阅读:1

Abstract

INTRODUCTION: Approximately 1% of the UK population is prescribed oral corticosteroids at any one time. It is not known how many of these patients present for major surgery. We aimed to establish the prevalence, characteristics and outcomes of patients taking oral corticosteroids. METHODS: We identified patients aged > 18 y undergoing major surgery between 1 April 2010 and 31 March 2020 from Hospital Episode Statistics with linked Clinical Practice Research Datalink data and the Office for National Statistics Mortality register in England. Prescribing data were used to define three sets of patients: 'low-dose' - taking ≤ 7.5 mg oral prednisolone equivalents per day for at least 28/91 days before surgery; 'high-dose' - taking > 7.5 mg oral prednisolone equivalents per day for at least 28/ 91 days before surgery; and a 'no-steroids' group. We used ≤ 7.5 mg of prednisolone equivalents per day as our threshold, as this would likely exclude almost all patients who were taking corticosteroids as replacement for absolute adrenal/pituitary deficiency. RESULTS: We identified 1,999,326 adult patients for inclusion in the dataset: 1,929,291 (96.5%) in the no-steroids; 63,353 (3.2%) in the low-dose group; and 6682 (0.3%) in the high-dose group. Median (IQR [range]) duration of hospital stay increased with increasing dose of corticosteroid (no-steroid 3 (0-14 [0-14,739]); low-dose 5 (1-26 [1-8079]); and high-dose 7 (2-28 [0-6956]) days). Mortality after the index surgery was 1.5%, 3.8% and 8.9% at 30 days and 5.5%, 11.6% and 39.9% at 1 year for no-steroids, low-dose and high-dose groups, respectively. CONCLUSION: Around 1 in 29 patients undergoing major surgery are taking oral corticosteroids for > 28 days in the 3 months before major surgery. Their outcomes are poor and warrant highlighting within care pathways to aid risk prediction and mitigation.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。